Law ❯ Litigation ❯ Securities Fraud

False Statements

Investor Claims Investor Losses Investor Damages Misleading Information Material Misrepresentation Corporate Accountability Corporate Executives

Corcept Faces Securities Class Action Over Relacorilant Disclosures as Firms Rally Investors Before April 21 Deadline

Plaintiffs say Corcept overstated relacorilant’s approval prospects in the face of FDA concerns.

Fermi Sued in SDNY After $150 Million Project Matador Funding Is Terminated